{"id":"mesoridazine","rwe":[{"pmid":"41392592","year":"2026","title":"Simultaneous Determination of Thioridazine and Its Metabolites by UHPLC-MS/MS With Application to a Pharmacokinetic Study in Rats.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"},{"pmid":"30000077","year":"2006","title":"Mesoridazine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39831535","year":"2025","title":"Lurasidone versus typical antipsychotics for schizophrenia.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"39414441","year":"2024","title":"Involvement of Proton-Coupled Organic Cation Antiporter in Human Blood-Brain Barrier Transport of Mesoridazine and Metoclopramide.","finding":"","journal":"Biological & pharmaceutical bulletin","studyType":"Clinical Study"},{"pmid":"36737927","year":"2023","title":"Study on morphological traits, nutrient compositions and comparative metabolomics of diploid and tetraploid Tartary buckwheat sprouts during sprouting.","finding":"","journal":"Food research international (Ottawa, Ont.)","studyType":"Clinical Study"}],"tags":[{"label":"Phenothiazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"DRD3","category":"gene"},{"label":"HTR2A","category":"gene"},{"label":"N05AC03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"drugInteractions":[{"url":"/drug/moxifloxacin","drug":"moxifloxacin","action":"Avoid combination","effect":"May interact with Moxifloxacin","source":"DrugCentral","drugSlug":"moxifloxacin"},{"url":"/drug/paroxetine","drug":"paroxetine","action":"Monitor closely","effect":"May interact with Paroxetine","source":"DrugCentral","drugSlug":"paroxetine"},{"url":"/drug/pindolol","drug":"pindolol","action":"Avoid combination","effect":"May interact with Pindolol","source":"DrugCentral","drugSlug":"pindolol"},{"url":"/drug/propranolol","drug":"propranolol","action":"Avoid combination","effect":"May interact with Propranolol","source":"DrugCentral","drugSlug":"propranolol"},{"url":"/drug/quetiapine","drug":"quetiapine","action":"Avoid combination","effect":"May interact with Quetiapine Fumarate","source":"DrugCentral","drugSlug":"quetiapine"},{"url":"/drug/quinine","drug":"quinine","action":"Monitor closely","effect":"May interact with Quinine","source":"DrugCentral","drugSlug":"quinine"},{"url":"/drug/ziprasidone","drug":"ziprasidone","action":"Avoid combination","effect":"May interact with Ziprasidone","source":"DrugCentral","drugSlug":"ziprasidone"}],"contraindications":["Coma","Conduction disorder of the heart","Congenital long QT syndrome","Epilepsy","Granulocytopenic disorder","Hyperkalemia","Hypokalemia","Neuroleptic malignant syndrome","Orthostatic hypotension","Predisposed to Torsades de Pointes Cardiac Arrhythmias","Prolonged QT interval","Stupor","Tardive dyskinesia"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MESORIDAZINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:38:20.350988+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:38:25.797892+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MESORIDAZINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:38:26.206981+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 2a (5-HT2a) receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:38:27.246115+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201052/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:38:26.907637+00:00"}},"allNames":"thioridazine-2-sulfoxide","offLabel":[],"synonyms":["mesoridazine besilate","mesoridazine","thioridazine-2-sulfoxide","mesoridazine besylate"],"timeline":[{"date":"1970-02-27","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1970-02-27","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Thioridazine-2-Sulfoxide","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"Histamine H1 receptor","novelty":"Follow-on","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"}],"modality":"Small Molecule","drugClass":"Phenothiazine","explanation":"","oneSentence":"","technicalDetail":"Mesoridazine acts as an antagonist at the histamine H1 receptor, which is involved in the regulation of arousal, attention, and memory. By blocking this receptor, mesoridazine can help to reduce the symptoms of schizophrenia, such as hallucinations and delusions."},"commercial":{"launchDate":"1970","_launchSource":"DrugCentral (FDA 1970-02-27, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1712","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MESORIDAZINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MESORIDAZINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:36:12.588895","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:38:28.529658+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"thioridazine","drugSlug":"thioridazine","fdaApproval":"1962-03-15","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"mesoridazine","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"thioridazine","brandName":"thioridazine","genericName":"thioridazine","approvalYear":"1962","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01231074","phase":"PHASE1","title":"Reducing Antipsychotic-Induced Weight Gain in Children With Metformin","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2010-02","conditions":["Obesity","Weight Gain","Psychotropic Induced Weight Gain"],"enrollment":96,"completionDate":"2013-05"},{"nctId":"NCT02582736","phase":"","title":"Antipsychotics and Risk of Hyperglycemic Emergencies","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2012-04","conditions":["Psychotic Disorders","Schizophrenia","Schizoaffective Disorder","Bipolar Disorder","Diabetes Mellitus, Type 2"],"enrollment":725489,"completionDate":"2012-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000147905","MMSL":"5058","NDDF":"001490","UNII":"5XE4NWM740","VUID":"4019816","CHEBI":"CHEBI:6780","VANDF":"4019063","INN_ID":"2019","RXNORM":"203186","UMLSCUI":"C0025497","chemblId":"CHEMBL1201052","ChEMBL_ID":"CHEMBL1088","KEGG_DRUG":"D00795","DRUGBANK_ID":"DB00933","PUBCHEM_CID":"4078","SNOMEDCT_US":"372852001","IUPHAR_LIGAND_ID":"7227","SECONDARY_CAS_RN":"32672-69-8","MESH_DESCRIPTOR_UI":"D008653","MESH_SUPPLEMENTAL_RECORD_UI":"C529599"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":184,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AC03","allCodes":["N05AC03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan","pmid":"41392592","title":"Simultaneous Determination of Thioridazine and Its Metabolites by UHPLC-MS/MS With Application to a Pharmacokinetic Study in Rats.","journal":"Biomedical chromatography : BMC"},{"date":"2006","pmid":"30000077","title":"Mesoridazine.","journal":""},{"date":"2025 Jan 20","pmid":"39831535","title":"Lurasidone versus typical antipsychotics for schizophrenia.","journal":"The Cochrane database of systematic reviews"},{"date":"2024","pmid":"39414441","title":"Involvement of Proton-Coupled Organic Cation Antiporter in Human Blood-Brain Barrier Transport of Mesoridazine and Metoclopramide.","journal":"Biological & pharmaceutical bulletin"},{"date":"2023 Feb","pmid":"36737927","title":"Study on morphological traits, nutrient compositions and comparative metabolomics of diploid and tetraploid Tartary buckwheat sprouts during sprouting.","journal":"Food research international (Ottawa, Ont.)"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1970","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1970-02-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1970-02-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1970-02-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1970-02-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1970-02-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1970-02-27T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:38:28.529658+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}